凯因科技 (688687)
Beijing Kawin Technology Share-Holding Co., Ltd.
K-Line Chart
No K-line data available
Company NameBeijing Kawin Technology Share-Holding Co., Ltd.
Listing Date2021-02-08
Issue Price18.98RMB
Registered Capital17094.442210k RMB
Legal RepresentativeZhou Desheng
Registered AddressBuilding 3, No. 6 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing
IndustryBiological Products
Main BusinessAn innovative biopharmaceutical enterprise focusing on the field of liver disease treatment, based on a biotechnology platform, committed to providing systemic solutions for liver disease treatment.
Company ProfileBeijing Kawin Technology Share-Holding Co., Ltd. (hereinafter referred to as Kawin Technology) was founded in 2008 with a registered capital of 127 million RMB. It is located in the Beijing Economic-Technological Development Area, a national-level economic and technological development zone known as the 'Medicine Valley'. Kawin Technology uses biotechnology as its platform, focuses on the field of viral diseases, and is committed to becoming a biopharmaceutical company that provides treatment solutions. It completed its shareholding system reform in 2010. In 2011, it successively introduced strategic partners such as Legend Capital, Haitong Kaiyuan, Cybernaut, and Lilly Asia Ventures. It has been selected as a Zhongguancun High-End Leading Enterprise, one of the Top 100 Zhongguancun Emerging Enterprises, and part of Beijing's Biopharmaceutical Industry Leapfrog Development (G20) Project.
Kawin Technology's R&D team consists of returnees and domestic doctors and masters, with expertise covering biomolecular science, pharmacology, process development, quality control, and formulation, fully possessing the technical capability for independent development of biological drugs. Relying mainly on an independent R&D model, and based on national key science and technology projects such as the '11th Five-Year Plan' and '12th Five-Year Plan', it has developed a series of innovative drugs with independent intellectual property rights, established an anti-viral product portfolio, and possesses drugs for treating hepatitis C.
Stock Details
1. Key Indicators
- Total Shares(W): 17094.44
- Circulating A-Shares(W): 17094.44
- Earnings Per Share(RMB): 0.6120
- Net Assets Per Share(RMB): 10.5077
- Operating Revenue(W RMB): 92685.82
- Total Profit(W RMB): 13082.15
- **Net Profit Attributable to Parent(W RMB) **: 10250.81
- Net Profit Growth Rate(%): -5.14
- Weighted Return on Equity(%): 5.5500
- Operating Cash Flow Per Share(RMB): 0.2220
- Undistributed Profit Per Share(RMB): 2.7805
- Capital Reserve Per Share(RMB): 6.6502
2. Main Business
The main business covers:
- Research, development, production, and sales of innovative drugs in the fields of virology and immunology
3. Company Basic Information
- Company Name: Beijing Kawin Technology Shareholding Co., Ltd.
- Listing Date: 2021-02-08
- Industry: Pharmaceutical Manufacturing
- Address: Building 3, No. 6 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing
- Website: https://www.kawin.com.cn
- Company Profile: The company was established by Kawin Biotechnology, Zhou Desheng, Deng Runlu, Zhang Chunli, He Chongfei, and Hou Yunde as joint promoters through a sponsorship method. It focuses on the research, development, production, and sales of innovative drugs for viral diseases.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Beijing Song'an Investment Management Co., Ltd. | Corporate Entity | 3840.00 | 22.46 |
| 2 | Beijing Kawin Technology Shareholding Co., Ltd. - 2025 Employee Stock Ownership Plan | Asset Management Plan | 350.90 | 2.05 |
| 3 | Beijing Funingwan Investment Management Center (Limited Partnership) | Corporate Entity | 210.13 | 1.23 |
| 4 | Beijing Funingwan Investment Management Center (Limited Partnership) | Corporate Entity | 122.47 | 0.72 |
| 5 | Shanghai Raimo Enterprise Management Consulting Co., Ltd. | Corporate Entity | 103.39 | 0.60 |
| 6 | Basic Pension Insurance Fund 2009 Portfolio | Social Security Fund | 87.26 | 0.51 |
| 7 | BARCLAYS BANK PLC | QFII | 84.23 | 0.49 |
| 8 | UBS AG | QFII | 83.84 | 0.49 |
5. Concept Sectors
- Gene Concept
- Generic Drugs
- Hepatitis Concept
- Innovative Drugs
Remarks
- Data update date: 2025-09-30
- Data source: Public Market Information